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Abstract
Background: We evaluated the safety and efficacy of induction chemotherapy with bevacizumab followed by
maintenance chemotherapy with bevacizumab for advanced non-small cell lung cancer (NSCLC) in this multicenter
phase II study.
Methods: Chemotherapy-naïve patient with stage IIIB–IV or recurrent nonsquamous NSCLC were eligible. We planned
approximately four cycles of induction cisplatin (75 mg/m2), pemetrexed (500mg/m2), and bevacizumab (15mg/kg)
followed by maintenance with pemetrexed (500 mg/m2) and bevacizumab (15 mg/kg) until disease progression.
Progression-free survival (PFS) was the primary endpoint.
Results: Forty patients received a median of four induction chemotherapy cycles. Of them, 35 (87.5%) patients
received a median of nine maintenance chemotherapy cycles. The objective response was 70.6%, and the
disease control rate was 97.1%. The median PFS was 10.8 (95% CI, 9.0–12.6), and overall survival was 48.0
(95% CI, 32.9–63.1) months. Median PFS of 23 patients with epidermal growth factor receptor (EGFR) mutations and of
16 patients without EGFR mutations were 12.9 (95% CI, 9.4–16.3) and 7.9 (95% CI, 1.1–14.7) months, respectively.
Toxicities graded ≥3 included neutropenia (15%), anemia (15%), hypertension (7.5%), anorexia (7.5%), fatigue
(7.5%), thromboembolic events (5%), jaw osteonecrosis (5%), nausea (2.5%), oral mucositis (2.5%), tumor pain
(2.5%), hyponatremia (2.5%), and gastrointestinal perforation (2.5%). Treatment-related deaths were not found.
Conclusions: In patients with advanced or recurrent nonsquamous NSCLC, induction chemotherapy with
cisplatin, pemetrexed, and bevacizumab followed by maintenance chemotherapy with pemetrexed and
bevacizumab is safe and effective regardless of their EGFR mutation status.
Trial registration: UMIN Clinical Trial Registry: UMIN000005569. Registered date: May 8, 2011.
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Background
Vascular endothelial growth factor (VEGF) is a strong
stimulator of endothelial cell proliferation. It is required
for maintaining tumor vasculature in various tumor
types [1, 2]. Bevacizumab is a recombinant humanized
monoclonal antibody, and it inhibits binding of VEGF to
its receptor [2]. Combination therapies of bevacizumab
and platinum-based doublet chemotherapy followed by
bevacizumab maintenance as a first-line treatment are
more superior than platinum-based doublet chemother-
apy with respect to the overall survival (OS) and
progression-free survival (PFS) in patients with advanced
nonsquamous non-small cell lung cancer (NSCLC) in
randomized controlled trials, such as the Eastern Co-
operative Oncology Group (ECOG) E4599 and AVAiL
[3, 4]. A phase III trial that compared front-line cisplatin
and gemcitabine with cisplatin and pemetrexed demon-
strated a treatment-by-histology interaction, showing an
improvement in OS with cisplatin and pemetrexed in
patients with nonsquamous NSCLC [5]. Thereafter, in a
large, randomized, phase III study, it was revealed that
maintenance chemotherapy with pemetrexed was effect-
ive and was well-tolerated in patients with advanced
nonsquamous NSCLC in whom the cancer did not show
progression after induction chemotherapy with peme-
trexed and cisplatin [6]. We hypothesized that induction
therapy with cisplatin, pemetrexed, and bevacizumab
followed by pemetrexed and bevacizumab maintenance
would result in better survival in patients with advanced
nonsquamous NSCLC. At the time of trial design in
2010, results of the AVAPERL [the randomized phase III
study comparing the efficacy of maintenance therapy
with bevacizumab (7.5 mg/kg) with that of maintenance
therapy with bevacizumab (7.5 mg/kg) plus pemetrexed
(500 mg/m2) after induction therapy with cisplatin (75
mg/m2), pemetrexed (500mg/m2), and bevacizumab
(7.5 mg/kg)] had not been reported [7].
In the present phase II trial, we aimed to evaluate the
safety and efficacy of induction therapy with cisplatin
(75 mg/m2), pemetrexed (500 mg/m2), and bevacizumab
(15 mg/kg) followed by maintenance therapy with peme-
trexed (500mg/m2) and bevacizumab (15 mg/kg) in pa-
tients with advanced or recurrent nonsquamous NSCLC.
Methods
Eligibility criteria
Patients were required to have nonsquamous NSCLC
and have not received any prior systemic chemotherapy,
except preoperative/postoperative adjuvant chemother-
apy or EGFR-tyrosine kinase inhibitor (TKI), with stage
IIIB, stage IV, or recurrence disease after surgery; have
measurable lesion that met the Response Evaluation Cri-
teria in Solid Tumors (RECIST) version 1.1 [8]; be aged
from 20 to 74 years; ECOG performance status of 0 or 1;
and have adequate organ function within 1 week before
study entry. The laboratory value requirements were as
follows: hemoglobin level ≥ 9 g/dl, absolute neutrophil
count ≥1500/mm3, platelet count ≥100,000/mm3, serum
bilirubin levels < 1.5 mg/dl, serum aspartate aminotrans-
ferase and alanine aminotransferase levels < 100 IU/l,
and serum creatinine levels < 1.5 mg/dl; have an esti-
mated life expectancy of at least 90 days; and have signed
the document of informed consent.
Patients were not eligible if they had metastases of the
central nervous system or prior therapies for brain me-
tastasis; had received radiotherapy for lung lesions; had a
history of cardiac effusion that required treatment; had
another active malignancy; had a history of hemoptysis
or hemosputum; had a complication related to a bleed-
ing episode, such as bleeding diathesis, an evidence of
major thoracic blood vessel involvement, an evidence of
cavity formation in the lung lesion, or an evidence of
thrombosis; needed an anti-thrombosis drug during the
study or were administered an anti-thrombosis drug
within 10 days before enrollment; had a history of brain
vascular disease with symptom, gastrointestinal perfor-
ation, diverticulitis, or fistula, symptomatic heart failure,
unstable angina or arrhythmia that required treatment,
cardiac infarction within 1 year before enrollment, any
evidence of interstitial lung disease, superior vena cava
syndrome, a cord compression, a serious non-healing
wound or unhealed bone fracture, an uncontrollable
ulcer, uncontrollable hypertension, or a serious concomi-
tant active infection that needed antibiotics; had known
sensitivity to any component of platinum or monoclonal
antibody drugs; or pregnancy or lactation.
The current study (UMIN000005569) was planned on
the basis of the Declaration of Helsinki and Good Clinical
Practice guidelines and was approved by the institutional
review boards of all participating hospitals. Signed in-
formed consent forms were obtained from the patients.
Treatment and evaluation
Prior to the administration of pemetrexed, all patients
received folic acid and vitamin B12 supplementation and
standard premedication with dexamethasone [2, 9, 10].
Patients received induction chemotherapy on day 1 of
each 21-day cycle comprising cisplatin (75 mg/m2),
pemetrexed (500 mg/m2), and bevacizumab (15 mg/kg).
Induction chemotherapy was repeated every 3 weeks
for a maximum of four cycles. After completion of at
least three cycles of induction chemotherapy, patients
underwent maintenance chemotherapy on day 1 of
the 21-day cycle comprising pemetrexed (500 mg/m2)
and bevacizumab (15 mg/kg). Every 3 weeks, mainten-
ance chemotherapy was repeated until disease pro-
gression or intolerance.
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Using the National Cancer Institute Common Toxicity
Criteria version 4.0, patients were evaluated every 21
days to assess toxicity. Tumor response was assessed
using computed tomography; it was performed every 6
weeks for 24 weeks and every 6 weeks thereafter until
disease progression. The original RECIST criteria (ver-
sion 1.1) were used to assess the response [8]. Central
review of radiologic assessment was not performed.
Statistical methods
PFS, defined as the time from enrollment to disease
progression (as assessed by the investigator) or to
death, was the primary endpoint of the study. OS, ob-
jective response rate, and toxicity were the secondary
endpoints. A median PFS of at least 7 months com-
pared with the historic rate of 4.8 months [5] would
be considered as a favorable outcome. We estimated
that 35 patients were needed to achieve an 80%
power with a one-sided 0.1 level test in this
single-stage, single-arm trial. An intent-to-treat ap-
proach was followed for analyzing all data. Kaplan–
Meier method was used to calculate survival distribu-
tions. All statistical analyses were performed using the
Statistical Package for the Social Sciences software
(version 24.0; IBM, Armonk, NY, USA). A p value of
< 0.05 was considered to be significant.
Results
Patients’ characteristics
We enrolled 40 eligible patients [median age, 64.5 years;
57.5% (23/40) men] to receive treatment between July
2011 and August 2014. Table 1 shows the patients’ char-
acteristics. Of all patients, 95% (38/40) had adenocarcin-
oma, 75.0% (30/40) had stage IV disease, and 57.5% (23/
40) had EGFR mutations.
The 40 eligible patients were administered a median of
four cycles (range, 1–4 cycles) of induction chemother-
apy comprising cisplatin, pemetrexed, and bevacizumab.
Of these patients, 35 (87.5%) were administered main-
tenance chemotherapy comprising pemetrexed and bev-
acizumab for a median of nine cycles (range, 1–54
cycles) (Table 2). Reasons for induction chemotherapy
discontinuation were disease progression (n = 1), un-
acceptable toxicity (n = 3), and patient request (n = 1).
Toxicity
Table 3 shows the grade 3 or 4 treatment-related toxicities
that developed in the patients. The proportion of patients
developing toxicities graded > 3 included 15.0% with neu-
tropenia, 15.0% with anemia, 7.5% with hypertension,
7.5% with anorexia, 7.5% with fatigue, 5% with a thrombo-
embolic event, 5% with jaw osteonecrosis, 2.5% with
Table 1 Patients’ characteristics
n = 40
Age (range) 64.5 (34–73)
Gender Male 23 (57.5%)
Female 17 (42.5%)
Performance status 0 34 (85.0%)
1 6 (15.0%)
Smoking history Yes 23 (57.5%)
Histology Adenocarcinoma 38 (95.0%)
Pleomorphic carcinoma 1 (2.5%)
Non-small cell lung cancer 1 (2.5%)
Stage IIIB 1 (2.5%)
IV 30 (75.0%)
Postoperative recurrence 9 (22.5%)









EGFR epidermal growth factor receptor, TKI tyrosine kinase inhibitor
Table 2 Chemotherapy administration and objective response
Induction therapy (n = 40) Median cycle (range) 4
(1–4)
Maintenance therapy (n = 35) Median cycle (range) 9
(1–54)




Table 3 Therapy toxicities (>Grade 3)
Grade 3 Grade 4
Neutropenia 5 (12.5%) 1 (2.5%)
Anemia 6 (15.0%) 0 (0%)
Hypertension 3 (7.5%) 0 (0%)
Anorexia 3 (7.5%) 0 (0%)
Fatigue 3 (7.5%) 0 (0%)
Thromboembolic event 2 (5.0%) 0 (0%)
Jaw osteonecrosis a 2 (5.0%) 0 (0%)
Nausea 1 (2.5%) 0 (0%)
Oral mucositis 1 (2.5%) 0 (0%)
Tumor pain 1 (2.5%) 0 (0%)
Hyponatremia 1 (2.5%) 0 (0%)
Gastrointestinal perforation 0 (0%) 1 (2.5%)
aThese two patients received denosumab
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nausea, 2.5% with oral mucositis, 2.5% with tumor pain,
2.5% with hyponatremia, and 2.5% with gastrointestinal
perforation. There were no treatment-related deaths.
Efficacy outcomes
This study met the primary endpoint. Median PFS was
10.8 (95% CI, 9.0–12.6), and OS was 48.0 (95% CI, 32.9–
63.1) months (Fig. 1a and b). The objective response rate
was 70.6%, and the disease control rate was 97.1% in pa-
tients with a measurable target lesion (n = 34) (Table 2).
On analyzing the relative change in the tumor size from
the baseline, we found that all patients (34/34) experi-
enced some degree of tumor shrinkage (Fig. 2).
The median PFS of patients with EGFR mutations
(n = 23) and those without the mutation (n = 16) were
12.9 (95% CI, 9.4–16.3) and 7.9 (95% CI, 1.1–14.7)
months, respectively (P = 0.36, Fig. 3a). Patients with
EGFR mutations (n = 23) did not reach a median OS,
and those without the mutation (n = 16) had a median
OS of 20.7 (95% CI, 15.8–25.6) months (P = 0.004;
Fig. 3b).
Discussion
We demonstrated the safety and efficacy of induction
therapy using cisplatin (75mg/m2), pemetrexed (500mg/
m2), and bevacizumab (15mg/kg) followed by mainten-
ance therapy with pemetrexed (500mg/m2) and bevacizu-
mab (15mg/kg) in patients with advanced or recurrent
nonsquamous NSCLC. Non-hematological toxicities
graded higher than 3 were not found in 10% of the pa-
tients, and a grade 4 non-hematological toxicity (gastro-
intestinal perforation) developed in only one (2.5%)
patient. Furthermore, there was no treatment-related
death in this study. The low frequencies of severe toxic-
ities observed in this study are consistent with those ob-
served in other studies [7, 11]. Serious adverse events such
as pulmonary embolism (1.6%) and pneumonia (5.6%) oc-
curred during maintenance therapy with pemetrexed and
Fig. 1 Progression-free survival (a) and overall survival (b) in patients with advanced or recurrent nonsquamous non-small cell lung cancer (n = 40)
Fig. 2 Best percentage change from the baseline in the sum of longest diameters of target lesions (n = 34)
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bevacizumab in the AVAPERL study, in which the bevaci-
zumab dose was 7.5mg/kg [7]. A retrospective study
evaluating the feasibility of cisplatin, pemetrexed, and bev-
acizumab (15mg/kg) in patients with advanced nonsqua-
mous NSCLC reported low frequencies of grade 3/4
non-hematologic toxicities (hypertension, 13%; pulmonary
thromboembolism, 3%; fatigue, 3%; anorexia, 6%; gastric
ulcer, 3%; and colitis, 3%) and no treatment-related
deaths [11]. To the best of our knowledge, this is the
first prospective study evaluating 15 mg/kg of bevaci-
zumab in combination with standard dose cisplatin
and pemetrexed for patients with nonsquamous
NSCLC; our results suggest that the dose of 15 mg/kg
bevacizumab and combination therapy with cisplatin,
pemetrexed, and bevacizumab followed by mainten-
ance therapy with pemetrexed and bevacizumab is a
safe and feasible regimen.
Regarding efficacy, this study met its primary endpoint
with a median PFS of 10.8 months, which is consistent
with the results of the phase III AVAPERL study (me-
dian PFS from induction treatment, 10.2 months) [7],
and seems superior to those of the PointBreak study
(carboplatin, pemetrexed, and bevacizumab followed
by pemetrexed and bevacizumab: the median PFS
from induction of treatment, 8.6 months) [9] and
those of the Pronounce study (carboplatin plus peme-
trexed followed by pemetrexed: the median PFS from
induction of treatment, 4.44 months) [12] (Table 4).
The objective response rate of 70.6% in the present
study is also excellent.
This study included 57.5% patients with EGFR muta-
tions. In our EGFR status-based sub-analysis, PFS of pa-
tients with EGFR mutations seemed longer (median PFS,
12.9 months) than that of those without the mutations
(median PFS, 7.9 months); however, this difference was
not significant. PFS of patients with EGFR mutations
who received cisplatin, pemetrexed, and bevacizumab in
the present study was similar to that of those who re-
ceived EGFR-TKIs in other studies (gefitinib, PFS of
9.2–10.8 months; erlotinib, PFS of 9.7–13.1 months; and
afatinib, PFS of 11–11.1 months) [13–18]. The standard
first-line treatment of patients with advanced NSCLC
and with EGFR mutation usually includes EGFR-TKIs;
however, a large retrospective study in a real world clin-
ical setting suggested that in patients with NSCLC and
EGFR mutations, sequential use of chemotherapy in
addition to EGFR-TKI improved OS compared with the
use of EGFR-TKI alone [19]. It is important not to miss
the opportunity of using the most effective chemother-
apy in such cases. Combination therapy with EFGR-TKI
Fig. 3 Progression-free survival (a) and overall survival (b) in patient subgroups based on their EGFR mutation status
Table 4 Progression-free survival and overall survival of cisplatin/carboplatin, pemetrexed with or without bevacizumab in patients
with nonsquamous non-small cell lung cancer
Study Phase Induction therapy Maintenance therapy PFS (months) OS (months)
Scagliotti, et al. [5] 3 CDDP + PEM – 5.3 11.8
PARAMOUNT [6] 3 CDDP + PEM PEM 6.9 –
AVAPEARL [7] 3 CDDP + PEM + BEV PEM + BEV 10.2 NR
PointBreak [23] 3 CBDCA + PEM + BEV PEM + BEV 8.6 17.7
PRONOUNCE [12] 3 CBDCA + PEM PEM 4.44 10.5
MAP (The current study) 2 CDDP + PEM + BEV PEM + BEV 10.8 48.0
PFS progression-free survival, OS overall survival, CDDP cisplatin, PEM pemetrexed, BEV bevacizumab, CBDCA carboplatin, NR not reached
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and cytotoxic agents may be another way to avoid miss-
ing to use chemotherapy, as a phase II study suggested
promising results of concurrent use of gefitinib, carbo-
platin, and pemetrexed [20]. Additional use of anti-an-
giogenic treatment is also promising for patients with
NSCLC with EGFR mutations. In addition to results of
the current study, a randomized phase II study reported
that erlotinib with bevacizumab showed better PFS than
erlotinib alone [21]. Moreover, a recent phase III study
demonstrated that combination therapy with atezo-
lizumab, bevacizumab, carboplatin, and paclitaxel
significantly improved PFS and OS compared with beva-
cizumab, carboplatin, and paclitaxel even in patients
with EGFR mutations [22]. Chemotherapy and bevacizu-
mab as well as EGFR-TKI may be potential key drugs to
improve prognosis of patients with nonsquamous
NSCLC with EGFR mutations. The excellent OS of pa-
tients with EGFR mutations in this study, with over 50%
patients with a 5-year OS rate, indicates that induction
therapy with cisplatin, pemetrexed, and bevacizumab
followed by maintenance therapy with pemetrexed and
bevacizumab can be an optional first-line treatment for
patients with advanced nonsquamous NSCLC and with
EGFR mutations.
Conclusions
A first-line combination therapy with cisplatin (75
mg/m2), pemetrexed (500 mg/m2), and bevacizumab
(15 mg/kg) followed by maintenance with pemetrexed
(500 mg/m2) and bevacizumab (15 mg/kg) is safe and
effective for patients with stage III, IV, or recurrent
nonsquamous NSCLC, and even for those with EGFR
mutations.
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